ChemotherapyFDA-approvedSecond-line
Irinotecan
How it works
Irinotecan is a topoisomerase I inhibitor that interferes with DNA replication, preventing cancer cells from growing and dividing.
Cancer types
Pancreatic Cancer— All patients
Efficacy
Irinotecan has been shown to improve overall survival and quality of life in patients with pancreatic cancer, although the response rates are generally modest.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing M6620 and Irinotecan in Patients with Advanced Solid Tumors | Lung Cancer | phase-1 | — | Source → |
| Cancer Cells' Fat Metabolism Linked to Chemotherapy Resistance | Colorectal Cancer | lab-study | — | Source → |
| Liposomal irinotecan shows promise in treating breast cancer with brain metastases | Breast Cancer | phase-2 | The intracranial objective response rate was 22.0% among patients with progressive brain metastases. | Source → |
| Combining Nanoparticles and Medication to Boost Pancreatic Cancer Treatment | Pancreatic Cancer | animal-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.